KR910000161A - 신속한 작용 발현을 가지는 정맥내 용액 - Google Patents

신속한 작용 발현을 가지는 정맥내 용액 Download PDF

Info

Publication number
KR910000161A
KR910000161A KR1019900007930A KR900007930A KR910000161A KR 910000161 A KR910000161 A KR 910000161A KR 1019900007930 A KR1019900007930 A KR 1019900007930A KR 900007930 A KR900007930 A KR 900007930A KR 910000161 A KR910000161 A KR 910000161A
Authority
KR
South Korea
Prior art keywords
alkyl
carbamazepine
cyclodextrin
etherified
solution
Prior art date
Application number
KR1019900007930A
Other languages
English (en)
Inventor
스테울레트 안네-프랑소아즈
슈무츠 마쿠스
메트리 라우렌트
베르나스코니 레이몬드
하인리히 스탈 페터
Original Assignee
베르너 발데그
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데그, 시바-가이기 에이지 filed Critical 베르너 발데그
Publication of KR910000161A publication Critical patent/KR910000161A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

신속한 작용 발현을 가지는 정맥내 용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. a) 카바마제핀 b) 용해제로서, C1-C4알킬 및/또는 하이드록시-C2-C4알킬에 의해 에테르화된 β-사이클로덱스트린(여기세어, 하이드록실 그룹의 위치는 C2-C4알킬 라디칼내 1-위치보다 높다) 및 c) 수성 담체 용액 및 경우에 따라, 다른 수용성 약제학적 보조제를 함유하는 카바카제핀의 정맥내 투여용 약제학적 조성물.
  2. 제1항에 있어서, a) 카바마제핀, b) 용해제로서, 2- 또는 3-하이드록시프로필 또는 2-하이드록시에틸에 의해 에테르화된 β-사이클로덱스트린 및 c) 수성 담체 용액 및 다른 수용성 약제학적 보조제를 함유하는 약제학적 조성물.
  3. 제1항에 있어서, a) 카바마제핀, b) 용해제로서, 2- 도는 3-하이드록시프로필에 의해 에테르화된 β-사이클로덱스트린(MDS= 약 0.25 내지 1 : 분자량 1300 내지 1600) 및 c) 수성 액제 비히클 및 다른 수용성 약제학적 보조재를 함유하는 약제학적 조성물.
  4. 제1항에 있어서, 주사 또는 주입용 용액의 형태인 약제학적 조성물.
  5. C1-C4알킬 및/또는 하이드록시-C2-C4알킬에 의해 에테르화된 β-사이클로덱스트린 유도체내 카바마제친의 봉입 화합물 및 경웨 따라 무수 생성물 제조용 수용성 보조제로 이루어진 무수 생성물.
  6. 제5항에 있어서, 2- 또는 3-하이드록시프로필-β-사이클로덱스트린 내 카바마제핀의 봉입 화합물로 이루어진 무수생성물.
  7. C1-C4알킬 및/또는 하이드록시-C2-C4알킬에 의해 에테르화된 β-사이클로덱스트린 유도체내 카바마제핀의 봉입 화합물(여기에서, 하이들고실 그룹의 위치는 C2-C4알킬 라디칼 내 1-위치보다 높다.)
  8. 제7항에 있어서, 2- 또는 3-하이드록시프로필-β-사이클로덱스트린으로 이루어진 봉입 화합물.
  9. α) C1-C4알킬 및/또는 하이드록시-C2-C4알킬에 의해 에테르화된 β-사이클로덱스트린(여기에서, 하이드록시 그룹의 위치는 C2-C4알킬 라디칼 내 1-위치보다 높다.)을 용해제로서 수성 담체 용액에 용해시키고, 카바마제핀 및 필요한 경우, 다른 수용성 약제학적 보조제를 담체 용액에 가하며, 필요한 경우 용액을 균질화시키거나, β) 활성물질 카바마제핀 및 C1-C4및/또는 하이드록시-C2-C4알킬에 의해 에테르화된 β-사이클로덱스트린을 함유하는 무수생성물(여기에서, 하이드록실 그룹의 위치가 C2-C4알킬 라디칼 내 1-위치보다 높다)을 제조하고, 필요한 경우 무수 생성물 제조용 수용성 보조제를 가하며, 무수 생성물을 수성 담체 용액에 용해시킴을 특징으로 하여, 제1항에 따른 약제학적 조성물을 제조하는 방법.
  10. 정맥내로 투여할 수 있는 카바마제핀 수용액의 제조를 위한, C1-C4알킬 및/또는 하이드록시-C2-C4알킬에 의해 에테르화된 β-사이클로덱스트린 유도체의 용도.
  11. 제10항에 있어서, 정캑내로 투여할 수 있는 카바마제핀 수용액의 제조를 위한 2- 도는 3-하이드록시 프로필-β-사이클로덱스트린의 용도.
  12. 인간 또는 동물의 치료학적 처리를 위한 방법에 사용하기 위한 카바마제핀의 안정한 정맥내 용액.
  13. 신경통 치료제 및/또는 진정제로서의 용도를 위한카바마제핀의 안정한 정맥내 용액.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900007930A 1989-06-02 1990-05-31 신속한 작용 발현을 가지는 정맥내 용액 KR910000161A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH208489 1989-06-02
CH2084/89-0 1989-06-02

Publications (1)

Publication Number Publication Date
KR910000161A true KR910000161A (ko) 1991-01-29

Family

ID=4225529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007930A KR910000161A (ko) 1989-06-02 1990-05-31 신속한 작용 발현을 가지는 정맥내 용액

Country Status (12)

Country Link
EP (1) EP0400609A1 (ko)
JP (1) JPH0320224A (ko)
KR (1) KR910000161A (ko)
AU (1) AU5594190A (ko)
CA (1) CA2017959A1 (ko)
DD (1) DD296841A5 (ko)
FI (1) FI902655A0 (ko)
HU (1) HUT57588A (ko)
IL (1) IL94514A0 (ko)
NO (1) NO902450L (ko)
PT (1) PT94219A (ko)
ZA (1) ZA904206B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010100420A (ko) * 2000-05-02 2001-11-14 이홍섭 필름 형태의 연마재를 갖는 초정밀 연마기에서 순차제어를이용한 자동화 방법 및 그 장치

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
US7189372B2 (en) 2000-03-01 2007-03-13 Kao Corporation Dissapating method and device and dissipating device for volatile components
RU2008133601A (ru) * 2006-01-17 2010-02-27 Риджентс Оф Дзе Юниверсити Оф Колорадо (Us) Центральное введение стабильных препаративных форм терапевтических агентов для состояний цнс
WO2009014762A1 (en) * 2007-07-25 2009-01-29 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
CN105726466A (zh) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 一种奥卡西平注射剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010100420A (ko) * 2000-05-02 2001-11-14 이홍섭 필름 형태의 연마재를 갖는 초정밀 연마기에서 순차제어를이용한 자동화 방법 및 그 장치

Also Published As

Publication number Publication date
JPH0320224A (ja) 1991-01-29
AU5594190A (en) 1990-12-06
IL94514A0 (en) 1991-03-10
ZA904206B (en) 1991-02-27
CA2017959A1 (en) 1990-12-02
HUT57588A (en) 1991-12-30
DD296841A5 (de) 1991-12-19
HU903303D0 (en) 1990-10-28
FI902655A0 (fi) 1990-05-28
PT94219A (pt) 1991-02-08
EP0400609A1 (de) 1990-12-05
NO902450D0 (no) 1990-06-01
NO902450L (no) 1990-12-03

Similar Documents

Publication Publication Date Title
FI86140C (fi) Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel.
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
EP0249008B1 (de) Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore
HRP980341A2 (en) Pharmaceutical formulations containing voriconazole
CA1333363C (en) Angiogenesis inhibitor comprising fumagillin
DE69430126D1 (de) Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts
MX174442B (es) Composiciones farmaceuticas y procedimiento para prepararlas
EA014513B1 (ru) Композиция иммуноконъюгата
DE68921760D1 (de) Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür.
KR960033470A (ko) 정맥내 투여용 나노현탁액
DE69627651D1 (de) Formulierungen und zusammensetzungen von in wasser schwer löslichen camptothecinderivaten
KR960704543A (ko) 악성 질환의 치료를 위한 비경구투여용 부설판(Parenteral Busulfan for treatment of malignant disease)
JPS61165322A (ja) スパガリン類の注射用凍結乾燥製剤
KR910000161A (ko) 신속한 작용 발현을 가지는 정맥내 용액
JPH03169812A (ja) トリアセチンを含む活性持続性注射用処方剤
ES2133380T3 (es) Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion.
KR880008801A (ko) 비경구 투여용 용액제
MC2280A1 (fr) Derives de galactomannanes utilisables pour le revetement ou l'enrobage de substances actives de medicaments
US5827850A (en) 1,2,4-benzotriazine oxides formulations
KR890012645A (ko) 레퍼퓨전(reperfusion)손상으로부터 포유동물 조직을 보호하기 위한 조성물 및 그의 제조방법
FI90824B (fi) Menetelmä kylmäkuivattujen farmaseuttisten fenyylikinoliinikarboksyylihappokoostumusten valmistamiseksi
US3526698A (en) Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol
US6818662B2 (en) Pharmaceutical composition
Al-Khafaji et al. The uptake of intravenous horseradish peroxidase by the guinea-pig inferior mesenteric ganglion.
ES2064104T3 (es) Procedimiento de preparacion de composiciones farmaceuticas del tipo de liberacion prolongada destinadas a la administracion por via oral.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid